Drugs / BELKYRA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06756490 | Dec 2024 → Dec 2026 expected | — | Sichuan Huiyu Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03712449 | Jan 2019 → Jul 2020 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT03425253 | Feb 2018 → Dec 2019 | — | Allergan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BELKYRA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712449 ↗ |
| Route | Subcutaneous | “injected into subcutaneous preplatysma fat tissue” NCT03425253 ↗ |